Royal Bank Of Canada Iveric Bio, Inc. Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$26.24 - $39.63 $74,075 - $111,875	-2,823 Reduced 16.68%	14,105 $554,000
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $182,331 - $239,852	-9,766 Reduced 36.59%	16,928 $411,000
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $308,630 - $428,752	17,902 Added 203.62%	26,694 $571,000
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $52,828 - $104,475	5,620 Added 177.18%	8,792 $158,000
Q2 2022 Aug 15, 2022	SELL	$9.12 - $18.9 $58,477 - $121,186	-6,412 Reduced 66.9%	3,172 $30,000
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $199,308 - $276,079	-16,404 Reduced 63.12%	9,584 $161,000
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $171,464 - $232,834	12,398 Added 91.23%	25,988 $435,000
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $31,348 - $77,595	4,434 Added 48.43%	13,590 $221,000
Q2 2021 Aug 16, 2021	BUY	$5.69 - $7.17 $52,097 - $65,648	9,156 New	9,156 $58,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.